Dalbavancin
Long-acting lipoglycopeptide for skin infections.
What it is
Dalbavancin (Dalvance) is a long-acting lipoglycopeptide antibiotic FDA-approved for acute bacterial skin and skin structure infections caused by susceptible gram-positive organisms. The long half-life allows weekly or single-dose treatment regimens.
Mechanism of action
Inhibits bacterial cell wall synthesis through binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors. Active against gram-positive organisms including MRSA.
Approved indications
Acute bacterial skin and skin structure infections.
Why this is out of scope at The Tide
IV antibiotic for serious skin/soft tissue infections, typically administered in hospital, ED, or infusion-center settings under infectious disease or appropriate physician care. Not appropriate for outpatient peptide clinic.
Where to learn more
Infectious disease specialists, emergency medicine, or hospital-based providers.